Trabecular versus cortical bone loss induced by GnRH agonists

References

• Cann O. E., Henzl M., Burry K., Andreyko J., Hanson F., Adamson G. D., Trobough G., Henrichs L., Stewart G. Reversible bone loss produced by the GnRH agonist nafarelin. Calcium Regulation mid Bone Metabolism, D. V. Cohn, T. J. Martin, J. P. Meunier. Excerpta Medica, Amsterdam 1987; volume 9: 123–127
   Google Scholar
• Devogelaert J. P., Huaux J. P., Thomas K., Nagant de Deuxchaisnes C. Differential effect of the Gn-RH agonist buserelin on the axial and the appendicular skeleton at different scanning sites. Preferential loss of trabecular bone. Osteoporosis, C. Christiansen, J. S. Johansen, B. J. Riis. Osteopress, Copenhagen 1987; 588–591
   Google Scholar
• Goulding A., Fisher L. Preventive effects of clomifene citrate on estrogen-deficiency osteopenia elicited by LHRH agonist administration in the rat. Journal of Bone and Mineral Research 1991; 6: 1177–1181
   Google Scholar
• Hansen M. A., Overgaard K., Riis B. J., Christiansen C. Role of peak bone mass and bone loss in postmenopausal osteoporosis: 12 year study. British Medical Journal 1991; 303: 961–964
   PubMed Web of Science ®Google Scholar
• Harris S., Dallal G. E., Dawson-Hughes B. Influence of body weight on rates of change in bone density of the spine, hip, and radius in postmenopausal women. Calcified Tissue International 1992; 50: 19–23
   PubMed Web of Science ®Google Scholar
• Hernández E. R., Revilla M., Rico H. A dual energy X-ray absorptiometry study. Total body bone mineral and pelvis bone mineral content as parameters of bone mass in men. Acta Anatomica 1991; 142: 227–230
   Google Scholar
• Holbrook T. L., Barret-Connor E., Klauber M., Sartoris D. A. A population-based comparison of quantitative dual-energy X-ray absorptiometry with dual-photon absorptiometry of the spine and hip. Calcified Tissue International 1991; 49: 305–307
   Google Scholar
• Johansen J. S., Riis B. J., Hassager C., Moen M., Jacobsen J., Christiansen C. The effect of a gonadotropin-release hormone agonist analog (nafarelin) on bone metabolism. Journal of Clinical Endocrinology and Metabolism 1988; 67: 701–706
   PubMed Web of Science ®Google Scholar
• Matta W. H., Shaw R. W., Hesp R., Katz D. Hypogonadism induced by luteinising hormone releasing hormone agonist analogues: effects on bone density in premenopausal women. British Medical Journal 1987; 294: 1523–1524
   PubMedGoogle Scholar
• Revilla M., Iritia M., Arribas I., Alvarez de los Heros J. I., Villa L. F., Rico H. Tartrate-resistant acid phosphatase as a biological marker of bone remodeling and turnover in women in relation to their gonadal state. Journal of Obstetrics and Gynecology 1992; 12: 191–194
   Google Scholar
• Rico H., Charro A., DePablos I., Bordiu E., Hernandez E. R., Espinos D. Lack of hormonal changes in postmenopausal women of equal weight with and without osteoporosis, including relation to time of menopause. Clinical Rheumatology 1984; 3: 337–343
   Google Scholar
• Rico H., Iritia M., Arribas I., Revilla M. Perfil biológico de la fosfatasa ácida tartrato resistente como marcador de la resorción ósea. Revista Espanola de Fisiologia 1990; 46: 379–384
   Google Scholar
• Rico H., Revilla M., Hernández E. R., Villa L. F., López-Alonso A. Total and regional bone mineral content in normal premenopausal women. Clinical Rheumatology 1991; 10: 423–425
   Google Scholar
• Rico H., Revilla M., Hernandez E. R., Villa L. F., Alvarez del Buergo M. Is pelvic bone mineral content assessed through dual energy X-ray absorptiometry an appropriate anatomical area for bone mass estimation in women?. Clinical Rheumatology 1992a; 11: 508–511
   Google Scholar
• Rico H., Revilla M., Hernandez E. R., Villa L. F., Alvarez del Buergo M. Total and regional bone mineral content in relation to menopause. Maturitas 1992b; 15: 233–240
   Google Scholar
• Rico H., Arnanz F., Revilla M., Perera S., Iritia M., Villa L. F., Arribas I. Total and regional bone mineral content in women treated with Gn-RH agonists. Calcified Tissue lnternational 1993; 52: 354–357
   Google Scholar
• Riis B. J., Christiansen C., Johansen J. S., Jacobson J. Is it possible to prevent bone loss in young women treated with luteinizing hormone-releasing hormone-agonists?. Journal of Clinical Endocrinology and Metabolism 1990; 70: 920–924
   PubMed Web of Science ®Google Scholar
• Russell-Aulet M., Wang J., Thornton J., Colt E. W.D., Pierson R. N. Bone mineral density and mass by total-body dual-photon absorptiometry in normal white and asian men. Journal of Bone and Mineral Research 1991; 6: 1109–1113
   Google Scholar
• Saggese G., Bertelloni S., Baroncelli G. I., Pardi D., Cinquanta L. Bone loss during gonadotropin-releasing hormone agonist treatment in girls with true precocious puberty is not due to an impairment of calcitonin secretion. Journal of Endocrinological Investigation 1991; 14: 231–236
   PubMed Web of Science ®Google Scholar
• Sartoris D. J., Resnick D. Current and innovate methods for noninvasive bone densitometry. Radiologic Clinics of North America 1990; 28: 257–278
   PubMedGoogle Scholar
• Scarnecchia L., Minisola S., Pacitti M. T., Carnevale V., Romagnoli E., Rosso R., Mazzuoli G. F. Clinical usefulness of serum tartrate-resistant acid phosphatase activity determination to evaluate bone turnover. Scandinavian Journal of Clinical and Laboratory Investigation 1991; 51: 517–524
   PubMed Web of Science ®Google Scholar
• Schiele F., Artur Y., Floc'h A., Siest G. Total, tartrate-resistant, and tartrate-inhibited acid phosphatases in serum:biological variations and reference limits. Clinical Chemistry 1988; 34: 685–490
   Google Scholar
• Stepan J. J., Pospichal J., Schreiber V., Kanka J., Mensik J., Presl J., Pacovsky V. The application of plasma tartrate-resistant acid phosphatase to assess changes in bone resorption in response to artificial menopause and its treatment with estrogen or norethisterone. Calcified Tissue International 1989; 45: 273–280
   Google Scholar
• Vaughan J. M. The Physiology of Bone, 2nd edition. Clarendon Press, Oxford 1975
   Google Scholar